DIDANOSINE (didanosine) by Aurobindo Pharma is [ see clinical pharmacology () ]. Approved for human immunodeficiency virus (hiv)-1 infection [ see clinical studies () ]. First approved in 2010.
Drug data last refreshed 22h ago
[ see Clinical Pharmacology () ].
Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children
A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection
A Study of Efavirenz in Combination With Stavudine and Didanosine
Worked on DIDANOSINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.